GAIN THERAPEUTICS INC

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

12 9 2023 09:25:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

28 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

10 8 2023 07:00:01 提供 Nasdaq GlobeNewswire

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®

07 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

31 7 2023 08:00:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics to Present at the Jefferies Healthcare Conference

01 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

12 5 2023 08:00:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease

03 5 2023 09:15:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

12 4 2023 16:30:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

29 3 2023 08:52:52 提供 Nasdaq GlobeNewswire

Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

23 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

22 3 2023 08:30:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

21 3 2023 08:00:01 提供 Nasdaq GlobeNewswire

Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

09 3 2023 08:00:03 提供 Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium

27 2 2023 08:00:01 提供 Nasdaq GlobeNewswire

Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences

02 2 2023 08:00:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

12 1 2023 16:05:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

10 11 2022 16:02:00 提供 Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons

26 9 2022 08:00:02 提供 Nasdaq GlobeNewswire

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

20 9 2022 07:30:00 提供 Nasdaq GlobeNewswire